BQBenjamin J. C. Quah

Benjamin J. C. Quah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benjamin J. C. Quah has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher Richard Parish

    Genome Sciences and Cancer Division, The John Curtin School of Medical Research, The Australian National University, Canberra, ACT 0200, Australia

    11 shared publications
  • Danushka Kumara Wijesundara

    Virology Laboratory, Basil Hetzel Institute for Translational Medicine, Discipline of Surgery, University of Adelaide, Adelaide, SA, Australia

    5 shared publications
  • Katharine Gosling

    Irradiation Immunity Interaction Lab, Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University

    5 shared publications
  • Terence J. O'NEill

    Bond Business School Bond University Gold Coast QLD Australia

    5 shared publications
  • David A. Simon Davis

    Irradiation Immunity Interaction Lab, Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University

    4 shared publications
  • Farhan M. Syed

    Irradiation Immunity Interaction Lab, Division of Genome Sciences and Cancer, John Curtin School of Medical Research, Australian National University

    4 shared publications

Latest Publications

  • Open Access

    An optimized spectral flow cytometry pipeline for longitudinal blood leukocyte immunophenotyping reveals stable, individually distinct immune signatures

    by Katharine Gosling, Jason Price, David A. Simon Davis, Farhan M. Syed, Benjamin J. C. Quah

    Introduction: Peripheral blood leukocyte immunophenotyping offers a minimally invasive insight into an individual’s immune system and is an attractive biomarker for detecting and monitoring disease. Advances in high-parameter spectral flow cytometry now resolve leukocyte subsets in unprecedented detail, but this depth adds complexity to sample preparation, acquisition and analysis, introducing technical variability that can obscure the biological signatures required for longitudinal monitoring. Methods: We built and validated an optimized, high-parameter spectral flow cytometry pipeline for repeated blood leukocyte profiling and asked whether the resulting signatures are stable and distinct enough to identify individuals over time. Results: Using rainbow beads and monoclonal-antibody spectra, we confirmed that instrument performance and spectral unmixing remained stable across more than two years, and that this dual measure localized faults to either the instrument or a reagent. Against a stabilized biological-invariant control, gating built on the dimensionality-reduction method PaCMAP was substantially more reproducible between operators than traditional two-dimensional gating and produced cleaner populations. Chemical fixation and one-week antibody pre-storage preserved leukocyte composition, whereas delayed processing and, more severely, cryopreservation altered it, the latter through near-complete granulocyte loss. Of the count-normalization schemes tested, normalization to the percentage of CD45 + leukocytes best preserved individual signatures over time, whereas counting-bead normalization performed worst. Applying the pipeline to ten donors sampled repeatedly across a year, we found that leukocyte signatures were dominated by stable, individually distinct differences between people — so distinct that a held-out visit could be assigned back to its donor, both by a trained random forest and by simple proximity to that donor’s own mean. Conclusion: Together these results define a technically sound, operator-reproducible and handling-robust pipeline whose normalized signatures capture a temporally stable individual immune fingerprint, providing a practical foundation for blood leukocyte profiling as a longitudinal biomarker of immune state in cancer and other diseases.

  • Open Access

    Cancer classification with radiomics in controlled preclinical models

    by Kyle Drover, David A. Simon Davis, Katharine Gosling, Jason Price, Naomi Otoo, Ines Atmosukarto, Kylie Jung, Hany Elsaleh, Farhan M. Syed, Benjamin J. C. Quah

    The premise of radiomics involves extracting high-dimensional quantitative features from medical images to aid clinical decision-making. While radiomics has shown promise in predicting disease characteristics, concerns regarding confounders, reproducibility, and interpretability limit its clinical adoption. In this study, we assessed the ability of radiomic features extracted from contoured CT images to classify two distinct tumour models, CT26 colorectal cancer (CRC) and 4T1 breast cancer (BC), in a highly controlled murine setting. We aimed to provide compelling data for the role of radiomics as a reliable cancer biomarker. We benchmarked radiomics-based classification against previously established blood-based biomarkers, including leukocyte populations and plasma proteins. Feature filtering reduced the original 1409 radiomic features to 18 non-redundant, high-importance predictors, primarily texture-based transformations. Unsupervised clustering via UMAP revealed that radiomics-based features did not segregate tumour types as effectively as blood biomarkers, suggesting potential confounding factors. Supervised machine learning using Random Forest showed that radiomic features achieved a classification accuracy of 0.87, lower than the 0.96 and 0.99 accuracies obtained with cell and plasma biomarkers, respectively. Furthermore, integrating radiomics with blood biomarkers did not enhance classification performance, and feature importance analysis using SHAP identified blood-based markers as the dominant predictors. These findings suggest that while radiomics retains some predictive value, it is less effective than blood biomarkers in this classification task and does not significantly contribute to multimodal tumour classification models. Our study underscores the need for further standardization and validation of radiomics before its clinical implementation.

  • Open Access

    Identifying cancer-associated leukocyte profiles using high-resolution flow cytometry screening and machine learning

    by David A. Simon Davis, Melissa Ritchie, Dillon Hammill, Jessica Garrett, Robert O. Slater, Naomi Otoo, Anna Orlov, Katharine Gosling, Jason Price, Desmond Yip, et al.

    Background: Machine learning (ML) is a valuable tool with the potential to aid clinical decision making. Adoption of ML to this end requires data that reliably correlates with the clinical outcome of interest; the advantage of ML is that it can model these correlations from complex multiparameter data sets that can be difficult to interpret conventionally. While currently available clinical data can be used in ML for this purpose, there exists the potential to discover new “biomarkers” that will enhance the effectiveness of ML in clinical decision making. Since the interaction of the immune system and cancer is a hallmark of tumor establishment and progression, one potential area for cancer biomarker discovery is through the investigation of cancer-related immune cell signatures. Hence, we hypothesize that blood immune cell signatures can act as a biomarker for cancer progression.Methods: To probe this, we have developed and tested a multiparameter cell-surface marker screening pipeline, using flow cytometry to obtain high-resolution systemic leukocyte population profiles that correlate with detection and characterization of several cancers in murine syngeneic tumor models.Results: We discovered a signature of several blood leukocyte subsets, the most notable of which were monocyte subsets, that could be used to train CATboost ML models to predict the presence and type of cancer present in the animals.Conclusions: Our findings highlight the potential utility of a screening approach to identify robust leukocyte biomarkers for cancer detection and characterization. This pipeline can easily be adapted to screen for cancer specific leukocyte markers from the blood of cancer patient.


  • Open Access

    Irradiation immunity interactions

    by David A Simon Davis, Ines I Atmosukarto, Jessica Garrett, Katharine Gosling, Farhan M Syed, Ben Jc Quah

    Summary: The immune system can influence cancer development by both impeding and/or facilitating tumour growth and spread. A better understanding of this complex relationship is fundamental to optimise current and future cancer therapeutic strategies. Although typically regarded as a localised and immunosuppressive anti‐cancer treatment modality, radiation therapy has been associated with generating profound systemic effects beyond the intended target volume. These systemic effects are immune‐driven suggesting radiation therapy can enhance anti‐tumour immunosurveillance in some instances. In this review, we summarise how radiation therapy can positively and negatively affect local and systemic anti‐tumour immune responses, how co‐administration of immunotherapy with radiation therapy may help promote anti‐tumour immunity, and how the use of immune biomarkers may help steer radiation therapy‐immunotherapy personalisation to optimise clinical outcomes.


  • Open Access

    Machine learning predicts cancer subtypes and progression from blood immune signatures

    by David A. Simon Davis, Sahngeun Mun, Julianne M. Smith, Dillon Hammill, Jessica Garrett, Katharine Gosling, Jason Price, Hany Elsaleh, Farhan M. Syed, Ines I. Atmosukarto, et al.

    Clinical adoption of immune checkpoint inhibitors in cancer management has highlighted the interconnection between carcinogenesis and the immune system. Immune cells are integral to the tumour microenvironment and can influence the outcome of therapies. Better understanding of an individual’s immune landscape may play an important role in treatment personalisation. Peripheral blood is a readily accessible source of information to study an individual’s immune landscape compared to more complex and invasive tumour bioipsies, and may hold immense diagnostic and prognostic potential. Identifying the critical components of these immune signatures in peripheral blood presents an attractive alternative to tumour biopsy-based immune phenotyping strategies. We used two syngeneic solid tumour models, a 4T1 breast cancer model and a CT26 colorectal cancer model, in a longitudinal study of the peripheral blood immune landscape. Our strategy combined two highly accessible approaches, blood leukocyte immune phenotyping and plasma soluble immune factor characterisation, to identify distinguishing immune signatures of the CT26 and 4T1 tumour models using machine learning. Myeloid cells, specifically neutrophils and PD-L1-expressing myeloid cells, were found to correlate with tumour size in both the models. Elevated levels of G-CSF, IL-6 and CXCL13, and B cell counts were associated with 4T1 growth, whereas CCL17, CXCL10, total myeloid cells, CCL2, IL-10, CXCL1, and Ly6Cintermediate monocytes were associated with CT26 tumour development. Peripheral blood appears to be an accessible means to interrogate tumour-dependent changes to the host immune landscape, and to identify blood immune phenotypes for future treatment stratification.


  • Open Access

    Custom-designed Small Animal focal iRradiation Jig (SARJ): design, manufacture and dosimetric evaluation

    by Jothy Selvaraj, Graham Rhall, Mounir Ibrahim, Talat Mahmood, Nigel Freeman, Zennon Gromek, Grant Buchanan, Farhan Syed, Hany Elsaleh, Ben J. C. Quah

    Objective: Preclinical animal models allow testing and refinement of novel therapeutic strategies. The most common preclinical animal irradiators are fixed source cabinet irradiators, which are vastly inferior to clinical linear accelerators capable of delivering highly conformal and precise treatments. The purpose of this study was to design, manufacture and test an irradiation jig (small animal focal irradiation jig, SARJ) that would enable focal irradiation of subcutaneous tumours in a standard fixed source cabinet irradiator. Methods and materials: A lead shielded SARJ was designed to rotate animal holders about the longitudinal axis and slide vertically from the base plate. Radiation dosimetry was undertaken using the built-in ion chamber and GAFChromic RTQA2 and EBT-XD films. Treatment effectiveness was determined by irradiating mice with subcutaneous melanoma lesions using a dose of 36 Gy in three fractions (12 Gy x 3) over three consecutive days. Results: The SARJ was tested for X-ray shielding effectiveness, verification of dose rate, total dose delivered to tumour and dose uniformity. Accurate and uniform delivery of X-ray dose was achieved. X-ray doses were limited to the tumour site when animal holders were rotated around their longitudinal axis to 15o and 195o, allowing sequential dose delivery using parallel-opposed tangential beams. Irradiation of subcutaneous melanoma tumour established on the flanks of mice showed regression. Conclusion: SARJ enabled delivery of tangential parallel-opposed radiation beams to subcutaneous tumours in up to five mice simultaneously. SARJ allowed high throughput testing of clinically relevant dose delivery using a standard cabinet-style fixed source irradiator. Advances in knowledge: A custom designed jig has been manufactured to fit into conventional cabinet irradiators and is dosimetrically validated to deliver clinically relevant dose distributions to subcutaneous tumours in mice for preclinical studies.


  • Open Access

    Cytolytic DNA vaccine encoding lytic perforin augments the maturation of- and antigen presentation by- dendritic cells in a time-dependent manner

    by Danushka K. Wijesundara, Wenbo Yu, Ben J. C. Quah, Preethi Eldi, John D. Hayball, Kerrilyn R. Diener, Ilia Voskoboinik, Eric J. Gowans, Branka Grubor-Bauk

    The use of cost-effective vaccines capable of inducing robust CD8+T cell immunity will contribute significantly towards the elimination of persistent viral infections and cancers worldwide. We have previously reported that a cytolytic DNA vaccine encoding an immunogen and a truncated mouse perforin (PRF) protein significantly augments anti-viral T cell (including CD8+T cell) immunity. Thus, the current study investigated whether this vaccine enhances activation of dendritic cells (DCs) resulting in greater priming of CD8+T cell immunity.In vitrodata showed that transfection of HEK293T cells with the cytolytic DNA resulted in the release of lactate dehydrogenase, indicative of necrotic/lytic cell death.In vitroexposure of this lytic cell debris to purified DCs from naïve C57BL/6 mice resulted in maturation of DCs as determined by up-regulation of CD80/CD86. Using activation/proliferation of adoptively transferred OT-I CD8+T cells to measure antigen presentation by DCsin vivo, it was determined that cytolytic DNA immunisation resulted in a time-dependent increase in the proliferation of OT-I CD8+T cells compared to canonical DNA immunisation. Overall, the data suggest that the cytolytic DNA vaccine increases the activity of DCs which has important implications for the design of DNA vaccines to improve their translational prospects.


  • Open Access

    Use of an In Vivo FTA Assay to Assess the Magnitude, Functional Avidity and Epitope Variant Cross-Reactivity of T Cell Responses Following HIV-1 Recombinant Poxvirus Vaccination

    by Danushka K. Wijesundara, Charani Ranasinghe, Ronald J. Jackson, Brett A. Lidbury, Christopher R. Parish, Benjamin J. C. Quah

    Qualitative characteristics of cytotoxic CD8+ T cells (CTLs) are important in measuring the effectiveness of CTLs in controlling HIV-1 infections. Indeed, in recent studies patients who are naturally resistant to HIV-1 infections have been shown to possess CTLs that are of high functional avidity and have a high capacity to recognize HIV epitope variants, when compared to HIV-1 infection progressors. When developing efficacious vaccines, assays that can effectively measure CTL quality specifically in vivo are becoming increasingly important. Here we report the use of a recently developed high-throughput multi-parameter technique, known as the fluorescent target array (FTA) assay, to simultaneously measure CTL killing magnitude, functional avidity and epitope variant cross-reactivity in real time in vivo. In the current study we have applied the FTA assay as a screening tool to assess a large cohort of over 20 different HIV-1 poxvirus vaccination strategies in mice. This screen revealed that heterologous poxvirus prime-boost vaccination regimes (i.e., recombinant fowlpox (FPV)-HIV prime followed by a recombinant vaccinia virus (VV)-HIV booster) were the most effective in generating high quality CTL responses in vivo. In conclusion, we have demonstrated how the FTA assay can be utilized as a cost effective screening tool (by reducing the required number of animals by >100 fold), to evaluate a large range of HIV-1 vaccination strategies in terms of CTL avidity and variant cross-reactivity in an in vivo setting.


  • Open Access

    The Use of Fluorescent Target Arrays for Assessment of T Cell Responses In vivo

    by Benjamin J. C. Quah, Danushka K. Wijesundara, Charani Ranasinghe, Christopher R. Parish

    The ability to monitor T cell responses in detail in vivo is important for the development of our understanding of the immune...